Pfizer
Compare Pfizer…Diversified pharma re-entering obesity via M&A: acquired Metsera November 2025 (~$7.3B upfront + up to $3.5B contingent) after danuglipron failed. Sciwind partnership ($495M) for ecnoglutide in China.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
PfizerDiversified pharma re-entering obesity via M&A: acquired Metsera November 2025 (~$7.3B upfront + up to $3.5B contingent) after danuglipron failed. Sciwind partnership ($495M) for ecnoglutide in China.
All metrics are vertically resized to show how they've changed over time. They're not on the same Y-axis. This chart is meant to compare trends, not values.
Values normalized to 0-100 scale for comparison. Hover for actual values.